1 Min Read
Nov 14 (Reuters) - ALMIRALL SA:
* SAYS ANTICIPATED APPROVAL FOR TILDRAKIZUMAB AND ITS LAUNCH IN EUROPE ARE MOVED FROM MID-2018 TO END OF 2018 OR EARLY 2019 Source text for Eikon:
Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.